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MaProprotein convertase subtilisin/kexin type 9 (PCSK9) binds to the low-density lipoprotein receptor, escorting it
to its destruction in the lysosome and thereby preventing the recirculation of the low-density lipoprotein receptor
to the hepatocyte cell surface. Both gain-of-function mutations in PCSK9 (causing marked increases in low-density
lipoprotein cholesterol [LDL-C] concentration and premature atherosclerosis) and loss-of-function mutations (causing
modest LDL-C reduction with low rates of coronary heart disease) have been described. Several monoclonal anti-
bodies to PCSK9 have achieved LDL-C reductions of 50% to 70% across various patient populations and back-
ground lipid therapies. Phase 2/3 trials have demonstrated good tolerability without clear drug-related toxicity,
although the number and duration of patients treated to date is modest. Currently, 4 phase 3 trials involving
>70,000 patients are testing whether these drugs reduce cardiovascular events. The U.S. Food and Drug Admin-
istration is currently reviewing the existing data to determine whether these agents could be made available prior
to the completion of these cardiovascular endpoint trials expected in 2018. (J Am Coll Cardiol 2015;65:2638–51)
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tein convertases, that activate a wide variety of pro-
teins regulating several key cellular pathways in
humans and other organisms (1), and the second
investigating genetic causes of familial hypercholes-
terolemia (FH) (2), were the parents of a potent new
class of low-density lipoprotein cholesterol (LDL-C)–
lowering drugs known as the proprotein convertase
subtilisin/kexin type 9 (PCSK9) inhibitors. In 2001,
scientists at Millennium Pharmaceuticals discovered
PCSK9 during studies of cerebellar neuron apoptosis,
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AB BR E V I A T I O N S
AND ACRONYM S
CHD = coronary heart disease
FH = familial
hypercholesterolemia
HDL = high-density lipoprotein
LDL-C = low-density
lipoprotein cholesterol
LDL-R = low-density
lipoprotein receptor
MoAb = monoclonal antibody
PCSK9 = proprotein
convertase subtilisin/kexin
type 9
SC = subcutaneous
= standard of care
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2639from the development of coronary heart disease (CHD)
(11). Thus, the stage was set for the development of
therapies that could inhibit PCSK9, lower LDL-C, and,
hopefully, reduce atherothrombotic events.
ROLE OF PCSK9 IN REGULATING
LDL-R METABOLISM
The principal route of clearance of circulating LDL-C
from the blood is via hepatocyte endocytosis—a
process mediated by binding of LDL-C to LDL-Rs on
the hepatocyte cell membrane (Central Illustration).
The typical LDL-R is able to recirculate back to the
cell surface up to 150 times, with PCSK9 playing
a critical role in LDL-R metabolism. The catalytic
subunit of PCSK9 binds to the epidermal growth
factor-like domain of the LDL-R and then escorts
the receptor to its degradation within the lysosome.
Given the counter-regulatory role played by PCSK9,
gain-of-function mutations in PCSK9 resulting in its
overexpression lead to fewer functioning LDL-Rs and
higher levels of circulating LDL-C. Conversely, loss-
of-function mutations in PCSK9 result in lower
LDL-C levels. PCSK9 can bind other proteins; appears
to play additional, lesser roles in lipid metabolism;
and its expression can be modiﬁed by a number of
factors (e.g., statins increase PCSK9 levels)—further
details can be found elsewhere (1,2).
THERAPEUTIC INHIBITION OF PCSK9
Studies in PCSK9 knockout mice demonstrated a 2- to
3-fold increase in LDL-Rs and a 25% to 50% decrease
in circulating cholesterol (12). This led to the explo-
ration of a number of methods to reduce PCSK9 levels
and/or inhibit its function, including both oral and
parenteral therapies (2) (Central Illustration). Both
antisense oligonucleotides and small interfering
ribonucleic acids have been studied in pre-clinical
and phase 1 human studies. Mimetic peptides, LDL-R
antagonists, small molecules, and gene silencing
approaches to modulate PCSK9 are in earlier stages of
development. A number of approaches using novel
small molecules have been described, including the
use of epidermal growth factor-A mimetics to block
PCSK9 binding of the LDL-R (13) and inhibitors of pro-
PCSK9 autoprocessing and/or secretion (14); unfor-
tunately, the PCSK9-LDL-R complex has a relatively
ﬂat surface that makes binding by a small molecule
inhibitor challenging (15). However, parenteral
monoclonal antibodies (MoAbs) have been the most
successful strategy to date and are now in late-stage
(phase 3 clinical trials) testing (Table 1); thus, they
are the focus of this paper.PCSK MONOCLONAL ANTIBODIES
The ﬁrst studies in humans in healthy vol-
unteers (16,17) were conducted with the fully
human PCSK9 MoAb REGN727 (hereafter
alirocumab) and, shortly thereafter, with the
fully human MoAb AMG145 (evolocumab [18])
and the humanized MoAb RN316 (bococizu-
mab [19]). These studies demonstrated dose-
dependent reductions in unbound PCSK9
levels beginning within hours after injection
with top doses achieving unmeasurable
PCSK9 levels for 2 weeks before returning to
baseline >6 weeks following a single injec-
tion. Dose-dependent reduction in LDL-C (up
to 70%), timing of nadir LDL-C (between 4
and 14 days), and delay in return to baseline LDL-C
(2 to 8þ weeks) were observed with each of these
MoAbs. More recently, data were presented with
LY3015014, a humanized MoAb with a unique epitope
that permits the normal proteolytic degradation of
PCSK9 (unlike other MoAbs), thereby resulting in a
more sustained lowering of LDL-C (20).
PHASE 2 CLINICAL TRIALS
Both alirocumab and evolocumab have been exten-
sively evaluated in more than a dozen phase 2 trials
exploring dose ranging and dose frequency, various
patient populations, and adjunctive lipid-lowering
therapies, with fewer studies available with bococi-
zumab (Table 2). The top doses being developed
of alirocumab (150 mg subcutaneously [SC] every
2 weeks) and evolocumab (140 mg SC every 2 weeks;
420 mg SC every 4 weeks) administered for 12 weeks
reduce LDL-C by approximately 60% to 70% (75 to
85 mg/dl) at trough (17,18) and >90% (>100 mg/dl) at
peak (21). The vast majority (70% to 90%) of patients
with hyperlipidemia treated with statin therapy were
able to achieve an LDL-C <70 mg/dl with alirocumab
(22) and evolocumab (23,24), demonstrating the
ability of these drugs to drive down levels of LDL-C to
ranges not possible with existing therapies. A phase 2
trial with bococizumab in 351 patients with hyper-
cholesterolemia reported LDL-C reductions of 53%
(53 mg/dl) with 150 mg every 2 weeks and by 41%
(45 mg/dl) with 300 mg every 4 weeks, adjusted for
placebo (19). A phase 2 trial comparing LY3015014
with placebo in 527 patients with hypercho-
lesterolemia treated with standard care (including
statins) revealed reductions in LDL-C of up to 58%
(w79 mg/dl) and 45% (w61 mg/dl) with adminis-
tration every 4 and 8 weeks, respectively, adjusted
for placebo (25).
SOC
CENTRAL ILLUSTRATION PCSK9 Function and Potential Targets for Therapeutics
Giugliano, R.P. et al. J Am Coll Cardiol. 2015; 65(24):2638–51.
SREBP-2 in hepatocytes regulates transcription of several lipids and proteins, including the low-density lipoprotein receptor (LDL-R) and proprotein convertase
subtilisin/kexin type 9 (PCSK9) (step 1). PCSK9 is processed in the endoplasmic reticulum into a mature form (step 2) and undergoes packaging by the Golgi apparatus
(as does the LDL-R) before being secreted (step 3). The LDL-R binds circulating low-density lipoprotein cholesterol (LDL-C) (step 4), and the pair is internalized in
endosomes, where LDL-C can be shuttled for other use. Meanwhile, the LDL-R recirculates to the cell surface (step 5) up to 150 times, removing additional LDL-C from
the circulation. PCSK9 regulates the number of LDL-R by binding to and internalizing the LDL-R (step 6), escorting it to its destruction in the lysosome (step 7). This does
not permit the LDL-R to recirculate. Several methods to interfere with the function of PCSK9 are shown by the letters within red octagons. Small interfering ribonucleic
acids (siRNAs) (A) can block transcription of PCSK9 messenger ribonucleic acid, whereas small molecular inhibitors (B) can disrupt the processing of PCSK9—both
approaches reduce the production of functional PCSK9. Two extracellular approaches to inhibit PCSK9 function include monoclonal antibodies (MoAbs) (C) and
adnectins (D) that prevent binding of PCSK9 to the LDL-R. SREBP ¼ sterol-binding regulatory element-binding transcription factor.
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2640In phase 2 studies, LDL-C was signiﬁcantly and
similarly lowered with alirocumab and evolocumab
compared with placebo, whether patients were taking
no, low-dose, or high-dose statins; taking ezetimibe; or
had heterozygous FH. The ﬁndings appear consistent
across major subgroups (e.g., age, sex, diabetes, risk
level) with no signiﬁcant treatment–subgroup inter-
actions consistently reported. Longer-term follow-up
($1 year) demonstrated a persistent similar reduction
in LDL-C as was observed in the 12-week studies.In addition, evolocumab reduced LDL-C in the
majority of patients with homozygous FH (26,27); the
responders had partially functioning (2% to 25%)
LDL-R. Genetic analyses in patients who did not
respond to evolocumab demonstrated nonfunc-
tioning LDL-Rs (<2% function) (26).
Both alirocumab and evolocumab also signiﬁcantly
reduce apolipoprotein B, total cholesterol, tri-
glycerides, and non–high-density lipoprotein choles-
terol (HDL); lipoprotein(a) (22,24,28,29), HDL, and
TABLE 1 Trial Acronyms
DESCARTES Durable Effect of PCSK9 Antibody Compared with Placebo Study
EBBINGHAUS Evaluating PCSK9 Binding antiBody Inﬂuence oN coGnitive HeAlth
in High cardiovascUlar Risk Subjects
FOURIER Further Cardiovascular Outcomes Research With PCSK9 Inhibition
in Subjects With Elevated Risk
GAUSS Goal Achievement After Utilizing an Anti-PCSK9 Antibody
in Statin Intolerant Subjects
LAPLACE LDL-C Assessment with PCSK9 Monoclonal Antibody Inhibition
Combined with Statin Therapy
MENDEL Monoclonal Antibody Against PCSK9 to Reduce Elevated LDL-C in
Subjects Currently Not Receiving Drug Therapy for Easing Lipid Levels
ODYSSEY LONG
TERM
Long-term Safety and Tolerability of Alirocumab in High Cardiovascular
Risk Patients with Hypercholesterolemia Not Adequately Controlled
with Their Lipid Modifying Therapy
OSLER Open-Label Study of Long-Term Evaluation Against LDL-C
PROFICIO Program to Reduce LDL-C and Cardiovascular Outcomes Following
Inhibition of PCSK9 in Different Populations
RUTHERFORD Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial
Hypercholesterolemia Disorder
SPIRE Studies of PCSK9 Inhibition and the Reduction of vascular Events
TESLA Trial Evaluating PCSK9 Antibody in Subjects with LDL-Receptor
Abnormalities
TIMI Thrombolysis In Myocardial Infarction
YUKAWA Study of LDL-Cholesterol Reduction Using a Monoclonal PCSK9 Antibody
in Japanese Patients With Advanced Cardiovascular Risk
LDL-C ¼ low-density lipoprotein cholesterol; PCSK9 ¼ proprotein convertase subtilisin/kexin type 9.
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2641apolipoprotein A are minimally (if at all) increased
(<10%), as would be expected given the mechanism
of action of these drugs. No reduction in C-reactive
protein has been reported, but it should be noted that
the populations studied would be expected to have
normal (or low) levels of C-reactive protein, and
studies in patients post-acute coronary syndromes
are ongoing.
No clear drug-related toxicities have been reported
in the phase 2 studies, although the duration of
therapy was generally short (12 weeks) and low-
frequency, but clinically relevant signals cannot be
excluded (30). One patient in an early phase 2 study
of alirocumab developed a leukocytoclastic reaction
(31); however, this has not been seen in subsequent
trials. No neutralizing antibodies have been reported
in the trials to date. A placebo-controlled study of
evolocumab in patients who were intolerant of sta-
tins has shown no excess in myalgias or other serious
adverse events compared with placebo (32). Other
theoretical safety concerns (33) on the basis of other
roles and targets of PCSK9 beyond LDL-R degrada-
tion include an increased risk for viral infections
(because some LDL-Rs function as viral entry re-
ceptors), insulin resistance and glucose intolerance
(reported in humans carrying the R46L PCSK9 loss-
of-function-mutation [34]), and increased visceral
adiposity, which is due to decreased free fatty acid
clearance related to changes in other lipoproteins
targeted by PCSK9 (35). Overall, across the phase 2
trials with a modest number of patient-years of
follow-up, cardiovascular events were infrequent
(30); longer-term safety experiences in a greater
number of patients are discussed in the following
section.
PHASE 3 AND LONGER-TERM
FOLLOW-UP STUDIES
Multiple larger phase 3 studies with alirocumab and
evolocumab evaluating lipid endpoints and longer-
term follow-up studies have been published or pre-
sented (Table 3).
PCSK9 MONOTHERAPY. Similar to the phase 2 trials
discussed previously, larger phase 3 trials with these
2 PCSK9 inhibitors have demonstrated consistent re-
ductions in LDL-C across a variety of patients and
background therapies. Both evolocumab and alir-
ocumab have been studied as monotherapies versus
ezetimibe (36,37). In 614 patients with baseline LDL-C
100 to 190 mg/dl, evolocumab reduced LDL-C at
12 weeks by 55% to 57% (w80 mg/dl) on average
compared with placebo, whereas ezetimibe achievedan 18% to 19% (w26 mg/dl) reduction (36). Similarly,
in a study of alirocumab monotherapy versus ezeti-
mibe in 103 patients with a 1% to 5% 10-year risk of
fatal cardiovascular events, alirocumab reduced
LDL-C by 47% (66 mg/dl) at 24 weeks, compared with
only 16% (22 mg/dl) for ezetimibe (37).
COMBINATION WITH STATIN. In 316 patients with
established CHD or CHD risk equivalents and hy-
percholesterolemia, alirocumab reduced LDL-C at
24 weeks by 46% (46 mg/dl) more than placebo, with
75% of patients achieving an LDL-C <70 mg/dl
(compared with 9% with placebo) (38). In a similar
population of patients who were taking maximally
tolerated statins, alirocumab reduced LDL-C by 30%
(31 mg/dl) more than ezetimibe, permitted more pa-
tients to achieve an LDL-C <70 mg/dl than ezetimibe
(77% vs. 46%), and had a similar safety proﬁle to
ezetimibe (39).
Evolocumab was compared with placebo and with
ezetimibe in 2,067 patients with an LDL-C$150 mg/dl,
all of whom were treated with either moderate or
intensive statin therapy (40). For patients on a high-
intensity statin (atorvastatin 80 mg or rosuvastatin
40 mg), evolocumab reduced the mean LDL-C
compared with placebo at 10 and 12 weeks by 66% to
75% (56 to 70 mg/dl) with 140 mg every 2 weeks and
by 63% to 75% (51 to 66 mg/dl) with 420 mg every
4 weeks. In patients receiving moderate-dose statins
TABLE 2 Phase 2 Trial Results
Trial Name (Ref. #) N
Baseline LDL-C
Entry Criteria,
Median (mg/dl) Drug and Dosing (mg)
LDL-C Reduction
vs. Placebo
In combination with statin
McKenney et al. (72) 183 $100, 127 Ali 50–150 Q2W 35%–67% at week 12
Ali 200–300 Q4W 38%–43% at week 12
Roth et al. (73) 92 >100, 123 Ali 150 Q2W 56% at week 8
LAPLACE-TIMI 57 (21) 631 $100, 123 Evo 70–140 Q2W 42%–66% at week 12
Evo 280–420 Q4W 42%–50% at week 12
YUKAWA (74) 310 $116, 143 Evo 70–140 Q2W 53%–69% at week 12
Evo 270–420 Q4W 58%–64% at week 12
Ballantyne et al. (75) 351 $80, 109 Boco 50–150 Q2W 35%–53% at week 12
Boco 200–300 Q4W 27%–41% at week 12
Kastelein et al. (25) 527 N/A, 135 LY3015014 20–300 Q4W 23%–58% at week 16
LY3015014 100–300 Q8W 23%–45% at week 16
Monotherapy
MENDEL (76) 406 100–190, 143 Evo 70–140 Q2W 37%–47% at week 12
Evo 280–420 Q4W 44%–53% at week 12
Statin intolerance
GAUSS (32) 160 >Goal, 193 Evo 280–420 Q2W 26%–36% at week 12
Evo 420 Q2W þ
ezetimibe 10 QD
47% at week 12
Heterozygous familial hypercholesterolemia
Stein et al. (16) 77 $100, 155 Ali 150 Q2W 57% at week 12
Ali 150–300 Q4W 18%–32% at week 12
RUTHERFORD (77) 169 $100, 156 Evo 350–420 Q4W 44%–56% at week 12
Homozygous familial hypercholesterolemia
TESLA (26) 8 $130, 440 Evo 420 Q4W 17%* at week 12
Trials appear in order of publication date; abstracts/presentations are listed after publications. *Change for baseline (no placebo group was tested).
Ali ¼ alirocumab; Boco ¼ bococizumab; Evo ¼ evolocumab; LDL-C ¼ low-density lipoprotein cholesterol; NA ¼ not available (entry criteria speciﬁed diagnosis of high
cholesterol); QD ¼ daily; Q2W ¼ biweekly; Q4W ¼ every 4 weeks; Q8W ¼ every 8 weeks; other abbreviations as in Table 1.
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40 mg), the corresponding reductions were 67% to
70% (75 to 84 mg/dl) and 63% to 69% (78 to 80 mg/dl)
with evolocumab dosed every 2 and 4 weeks,
respectively. Reductions with ezetimibe were less
than one-half of that achieved with evolocumab,
regardless of the background statin. On a background
of high-intensity statin, the mean achieved LDL-C
with evolocumab was 33 to 38 mg/dl, with >90%
achieving an LDL-C <70 mg/dl.
COMBINATION WITH STATIN ± EZETIMIBE. In a
52-week placebo-controlled randomized trial of evo-
locumab in 901 patients with hypercholesterolemia
treated with diet alone, atorvastatin 10 mg, atorvas-
tatin 80 mg, or atorvastatin 80 mg þ ezetimibe 10 mg
(background therapy dependent upon Adult Treat-
ment Panel 3 risk level), evolocumab reduced LDL-C
by 57% (57 mg/dl) on average compared with pla-
cebo (range 49% to 62% across the various back-
ground therapies) after 52 weeks of therapy (41). The
mean achieved LDL-C at week 52 ranged from 45 to
64 mg/dl with evolocumab, and the LDL-C was
reduced <70 mg/dl in 82% of patients (compared with6% with placebo). Among 189 patients who received
atorvastatin 80mgþ ezetimibe 10mg, themean LDL-C
values fell from 117 to 64 mg/dl with evolocumab
versus 120 to 115 mg/dl with placebo, and 67% and
11% had an LDL-C <70 mg/dl at week 52, respectively.
PATIENTS WITH STATIN INTOLERANCE. Two phase
3 trials (42,43) in statin-intolerant patients have
demonstrated the efﬁcacy and tolerability of PCSK9
inhibitors in this challenging population. In a ran-
domized placebo-controlled trial of 307 patients
intolerant to 2 or more statins whose LDL-Cs were not
at goal as deﬁned by Adult Treatment Panel 4, both
evolocumab 140 mg every 2 weeks and 420 mg every
4 weeks reduced LDL-C at 12 weeks by 53% to 56% (99
to 106 mg/dl) compared with 15% to 18% (30 to 36
mg/dl) for ezetimibe (42). Preliminary results of a
placebo-controlled study of 314 patients with base-
line LDL-C averaging 190 mg/dl who were intolerant
of 2 or more statins (of which 1 was at a low dose) due
to myalgia randomized to alirocumab (75 mg every
2 weeks with optional up-titration to 150 mg every
2 weeks), ezetimibe 10 mg daily, or atorvastatin
20 mg daily were reported at the 2014 American Heart
TABLE 3 Phase 3 and Long-Term Extension Trial Results
Trial Name N
Baseline LDL-C
Entry Criteria,
Median (mg/dl) Drug and Dosing (mg) LDL-C Reduction vs. Placebo
Monotherapy
MENDEL-2 (36) 614 100–190, 143 Evo 140 Q2W 57% and 39%* at 10–12 weeks†
Evo 420 Q4W 57% and 40%* at 10–12 weeks†
ODYSSEY MONO (78) 103 100–190, 140 Ali 75 Q2W‡ 32%* at week 24
In combination with statin
LAPLACE-2 (40) 2,067 $150, 109 Evo 140 Q2W 66%–75% and 44%–46%* at weeks 10–12†
Evo 420 Q4W 63%–75% and 39%–55%* at weeks 10–12†
ODYSSEY COMBO II (39) 720 $70, 108 Ali 75 Q2W‡ 30%* at week 12
ODYSSEY COMBO I (38) 316 $70, 97 Ali 75 Q2W‡ 46% at week 24
YUKAWA-2 (79) 404 $100, N/A Evo 140 Q2W 74%–75% at weeks 10–12†; 75%–76% at week 12
Evo 420 Q4W 66%–81% at weeks 10–12†; 61%–76% at week 12
In addition to diet alone, statin, or statin þ ezetimibe
DESCARTES (41) 901 $75, 104 Evo 420 Q4W 49%–62% at week 52
ODYSSEY CHOICE I (80) 803 >Goal, 122 Ali 75 Q2W
Ali 300 Q4W 52%–59% at week 24
Statin intolerance
GAUSS-2 (42) 307 >Goal, 193 Evo 140 Q2W 38%* at week 12; 38%* at weeks 10–12†
Evo 420 Q4W 38%* at week 12; 39%* at week 10–12†
ODYSSEY ALTERNATIVE (44) 314 >Goal, 191 Ali 75 Q2W‡ 30%* at week 24
ODYSSEY CHOICE II (80) 233 >Goal, 158 Ali 75 Q2W‡ 56% at week 24
Ali 150 Q4W§ 56% at week 24
Heterozygous familial hypercholesterolemia
RUTHERFORD-2 (45) 331 $100, 154 Evo 140 Q2W 59% at 12 weeks; 60% at weeks 10–12†
Evo 420 Q4W 61% at 12 weeks; 66% at weeks 10–12†
ODYSSEY FH I and II (47) 735 $160, 141 Ali 75 Q2W‡ 51%–58% at week 24
Homozygous familial hypercholesterolemia
TESLA Part B (27) 50 $130, 347 Evo 420 Q4W 31% at week 12
Long-term extension studies
OSLER-1 (48) and OSLER-2 (24) 1,359 $100, 120 Evo 420 Q4W 52% at week 52 (vs. standard of care)
ODYSSEY LONG TERM (22) 2,341 $70, 122 Ali 150 Q2W 62% at week 24
Trials appear in order of publication date; abstracts/presentations are listed after publications. See Table 1 for some trial acronyms. *Versus ezetimibe 10 mg QD. †Mean of the
reductions at weeks 10 and 12. ‡Dose adjusted to 150 mg Q2W if LDL-C not at target (target either <70 or <100 mg/dl, depending on risk) at week 12. §Dose adjusted to 75 mg
if LDL-C <25 mg/dl at weeks 8–12.
ODYSSEY ALTERNATIVE¼ Study of Alirocumab in Patients With Primary Hypercholesterolemia and Moderate, High, or Very High Cardiovascular (CV) Risk, Who Are Intolerant
to Statins; ODYSSEY CHOICE ¼ Study to Evaluate the Efﬁcacy and Safety of an Every Four Weeks Treatment Regimen of Alirocumab in Patients With Primary Hypercholes-
terolemia; ODYSSEY COMBO ¼ Efﬁcacy and Safety of Alirocumab Versus Placebo on Top of Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hyper-
cholesterolemia; ODYSSEY FH ¼ Efﬁcacy and Safety of Alirocumab Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial
Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy; ODYSSEY MONO ¼ Efﬁcacy and Safety of Alirocumab Versus Ezetimibe in Patients With
Hypercholesterolemia; other abbreviations as in Tables 1 and 2.
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2643Association Scientiﬁc Sessions (44). Alirocumab not
only was signiﬁcantly more effective in reducing
LDL-C (absolute decline of 84 mg/dl compared with
33 mg/dl for ezetimibe), but also had the lowest rate
of muscle-related adverse events (33% vs. 41% ezeti-
mibe [p ¼ 0.10] vs. 46% atorvastatin [p ¼ 0.04]).
FAMILIAL HYPERCHOLESTEROLEMIA. Evolocumab
has completed separate phase 3 trials in patients
with heterozygous (45) and with homozygous FH
(27); alirocumab has been studied in patients with
heterozygous FH in phase 3 (46). A placebo-controlled
trial of 331 patients with heterozygous FH taking
statin  additional lipid-lowering agents demon-
strated that both evolocumab 140 mg every 2 weeksand 420 mg every 4 weeks signiﬁcantly reduced
LDL-C by approximately 60% (90 to 95 mg/dl)
compared with placebo (45). Similar preliminary
ﬁndings were reported with alirocumab at the
European Society of Cardiology Congress in 2014 (47).
Analyses of 2 trials, enrolling a total of 732 patients
with heterozygous FH on a maximally-tolerated
dose of statin  other lipid-lowering therapy, showed
51% to 58% (66 to 85 mg/dl) reductions in LDL-C at
24 weeks with alirocumab compared with placebo.
The only phase 3 trial conducted in patients with
homozygous FH enrolled 50 patients with $4 weeks
of a stable lipid regimen and demonstrated a 31%
relative (93 mg/dl absolute) further reduction from
FIGURE 1 Cardiovascular Events in Long-Term PCSK9 Trials
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Rates of composite adjudicated cardiovascular events in the
ODYSSEY OUTCOMES (left) and OSLER (Open-Label Study of
Long-Term Evaluation Against LDL-C) 1 and 2 (right) trials. In the
ODYSSEY OUTCOME trial, the post-hoc cardiovascular endpoint
was a composite of coronary heart disease death, nonfatal
myocardial infarction, fatal or nonfatal ischemic stroke, and un-
stable angina requiring hospitalization, assessed after an average
follow-up of 65 weeks. In the OSLER trials, the pre-speciﬁed
cardiovascular endpoint was a composite of death, myocardial
infarction, unstable angina requiring hospitalization, coronary
revascularization, stroke, transient ischemic attack, and heart
failure requiring hospitalization, assessed after an average
follow-up of 11.1 months. Hazard ratios (HRs) are derived from
analyses of Kaplan-Meier event rates. PCSK9 ¼ proprotein
convertase subtilisin/kexin type 9; SOC ¼ standard of care.
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placebo (27).
LONGER-TERM TREATMENT. Larger and longer-term
studies provide further information regarding the
durability of lipid-lowering effects and safety of
PCSK9 inhibitors. In the OSLER I (Open-Label Study
of Long-Term Evaluation against LDL Cholesterol)
study (48), 1,104 patients who completed 1 of 4 phase
2 studies with evolocumab entered an open-label
controlled study comparing evolocumab 420 mg
every 4 weeks plus standard of care (SOC) to SOC
alone. The LDL-C reduction with evolocumab þ SOC,
as compared with SOC alone, remained constant
at approximately 52% (w73 mg/dl) for the entire
52-week period. More patients receiving evolocumab
achieved LDL-C <100 mg/dl (96% vs. 32%), <70 mg/dl
(83% vs. 4%), <50 mg/dl (56% vs. 0.5%), and
<25 mg/dl (13% vs. 0%) (p < 0.001 for each compari-
son with SOC alone). The tolerability of longer-term
evolocumab was good (only 3.7% developed adverse
events that led to discontinuation of evolocumab),
and serious adverse events occurred in a similar
number of patients who received evolocumab þ SOC
(7.1%) as with SOC alone (6.3%). Adverse events were
not increased among the 98 patients receiving evo-
locumab who achieved an LDL-C <25 mg/dl compared
with those achieving higher LDL-C levels or compared
with patients receiving SOC only.
A pre-speciﬁed combined analysis of 4,465 pa-
tients who completed 1 of 12 phase 2 or 3 studies of
evolocumab and who were then randomized to either
evolocumab plus SOC versus SOC alone in an open-
label extension study over an average of 11 months,
was conducted across the OSLER 1 and 2 studies (24).
Evolocumab 420 mg every 4 weeks reduced the
average LDL-C by 61% from 120 to 48 mg/dl at 12
weeks. Adverse events (the primary study endpoint)
occurred in 69% of patients treated with evolocumab
versus 65% in the SOC group, with no difference in
the rate of serious adverse events (7.5% in each
group). Only 2.4% of patients in the evolocumab
group stopped treatment due to an adverse event.
Neurocognitive events were reported more
frequently with evolocumab (0.9% vs. 0.3%), with no
apparent relationship to the achieved LDL-C. The
ongoing EBBINGHAUS (Evaluating PCSK9 Binding
antiBody Inﬂuence oN coGnitive HeAlth in High car-
diovascUlar Risk Subjects) study (NCT02207634) is
prospectively evaluating this issue in a subgroup of
patients with apparently normal cognitive function
enrolled in a phase 3 cardiovascular outcomes study
with evolocumab (49). The pre-speciﬁed composite
of death, myocardial infarction, hospitalization for
unstable angina, coronary revascularization, stroke,transient ischemic attack, and hospitalization for
heart failure was reduced by 53% (95% conﬁdence
interval: 22% to 72%; p ¼ 0.003) (Figure 1). Although
promising, the modest number of cardiovascular
events (n ¼ 60), an exploratory, albeit adjudicated,
endpoint in this analysis, requires conﬁrmation in an
adequately-powered trial.
In the ODYSSEY LONG TERM (Long-term Safety
and Tolerability of Alirocumab in High Cardiovas-
cular Risk Patients with Hypercholesterolemia Not
Adequately Controlled with Their Lipid Modifying
Therapy) placebo-controlled trial in 2,341 patients
with hyperlipidemia on maximally tolerated statin
who were at high risk for CHD, alirocumab reduced
LDL-C by 62% at 24 weeks compared with placebo
(achieved mean LDL-C 119 mg/dl with placebo vs. 48
mg/dl with alirocumab) (22). More patients achieved
an LDL-C <70 mg/dl at week 24 with alirocumab
compared with placebo (79% vs. 8%; p < 0.001).
Patients in the alirocumab group had higher rates of
injection-site reactions 5.9% vs. 4.2%), myalgia (5.4%
vs. 2.9%), neurocognitive events (1.2% vs. 0.5%), and
ophthalmologic events (2.9% vs. 1.9%) over a period
of 78 weeks. As was observed with evolocumab, rates
of adverse events among 575 (37%) patients who
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tive readings was similar to the overall alirocumab
group. In a post-hoc analysis of selected cardiovas-
cular events with alirocumab, the time to ﬁrst adju-
dicated major cardiovascular event (a composite of
CHD death, myocardial infarction, ischemic stroke, or
unstable angina requiring hospitalization) was less
frequent with alirocumab than with placebo (hazard
ratio: 0.52; 95% conﬁdence interval: 0.31 to 0.90).
Conﬁrmation of these ﬁndings in a prospectively
designed cardiovascular outcomes trial is needed,
given the small number of events (n ¼ 53) in this
post-hoc analysis.
It is of interest to compare the reduction in car-
diovascular events observed, given the degree of
LDL-C reduction obtained with PCSK9 inhibitors, in
these 2 recent analyses in the context of the rela-
tionship between LDL-C reduction and major vascular
events reported in the CTT (Cholesterol Treatment
Trialists) meta-analysis (50). The latter analysis
demonstrated a 22% reduction in major vascular
events for each 1 mmol/l reduction in LDL-C in an
analysis of >170,000 patients from 27 randomized
trials of cholesterol lowering—a relationship that
remained consistent across a broad range of base-
line LDL-C values. Given the LDL-C reduction (70 to
72 mg/dl or 1.8 to 1.9 mmol/l) observed in the OSLER
1 and 2 and ODYSSEY LONG-TERM analyses, the
CTT meta-analysis would have predicted a reduction
of just over 40% in major vascular events—a value
that falls well within the conﬁdence interval of
the observed results. Ongoing phase 3 trials that
are adequately powered to examine cardiovascular
events are ongoing.
PHASE 3 CLINICAL OUTCOME TRIALS
There are 4 ongoing large, placebo-controlled phase
3 trials in >70,000 patients investigating whether
PCSK9 inhibitors on a background of statin reduce
cardiovascular events (Figure 2). In the ODYSSEY
Outcomes trial (51), 18,000 patients 1 to 12 months
post–acute coronary syndrome treated with
maximally-tolerated atorvastatin or rosuvastatin are
being randomized to subcutaneous alirocumab or
placebo every 2 weeks. All patients must have either
an LDL-C $70 mg/dl, non-HDL total cholesterol
$100mg/dl, or apolipoprotein B$80mg/dl. The initial
dose of alirocumab is 75 mg, with drug discontinua-
tion for LDL-C <15 mg/dl on repeated measurements,
and up-titration to 150 mg for LDL-C $50 mg/dl.
In the FOURIER (Further Cardiovascular Outcomes
Research With PCSK9 Inhibition in Subjects With
Elevated Risk) trial (52), 27,500 stable patients withprior MI, ischemic stroke, or peripheral arterial
disease treated with optimal-dose statin are being
randomized to SC evolocumab or placebo. All pa-
tients must have either an LDL-C $70 mg/dl or non-
HDL total cholesterol of $100 mg/dl. The dose of
evolocumab is 140 mg every 2 weeks or 420 mg
every 4 weeks; these 2 regimens achieve similar
reductions of LDL-C over time (43). No adjustment
of the dose of evolocumab is permitted on the
basis of LDL-C values, although patients may select
whether they prefer the every 2-week or every
4-week regimen.
Two placebo-controlled phase 3 trials (53,54) in
patients at high risk for cardiovascular events are
assessing whether bococizumab 150 mg SC every
2 weeks reduces cardiovascular events. The entry
criteria are similar, except that SPIRE-1 (Studies of
PCSK9 Inhibition and the Reduction of vascular
Events-1) (53) is enrolling 17,000 patients with LDL-C
between 70 and 100 mg/dl, whereas in SPIRE-2 (54),
9,000 patients with LDL-C $100 mg/dl are being
enrolled.
Completion of these 4 trials is projected for late
2017. In the interim, the U.S. Food and Drug Admin-
istration is currently evaluating both alirocumab and
evolocumab on the basis of phase 2 and 3 studies
completed through mid-2014. Thus, while we await
the results from the ongoing phase 3 outcomes trials,
it is possible that PCSK9 inhibitors may be available
before then for use in selective high-risk patients
who are not able to achieve the desired LDL-C level
(e.g., FH, statin-intolerant).
CLINICAL IMPLICATIONS
FOR INDIVIDUAL PATIENTS
Given the consistent effects on LDL-C that have been
reported with MoAbs to PCSK9 in a wide variety of
clinical scenarios, the most obvious beneﬁt to indi-
vidual patients is that a dramatically lower LDL-C
level can be achieved, with a high likelihood of
reaching <70 mg/dl. A remarkable feature of the
MoAb to PCSK9 is that the LDL-C reduction is sus-
tained for 2 to 8 weeks after a single SC injection,
depending on the dose and the MoAb binding it.
Patients with FH (recent estimates in the general
population are 1 in 200 for heterozygous FH [55] and
as many as 1 in 160,000 for homozygous FH [56])
typically do not achieve recommended levels of
LDL-C with currently available oral therapies (57);
thus, FH patients stand to beneﬁt the most from
treatment with a PCSK9 inhibitor. In addition, pa-
tients with hypercholesterolemia who are intolerant
to high doses of statin or have a less than expected
FIGURE 2 Phase 3 Designs for Cardiovascular Endpoint Trials
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(>90% in some studies) of achieving an LDL-C
<70 mg/dl. Only the rare patient with homozygous
FH and <2% LDL-R activity (so-called null mutations)have shown a lack of response to PCSK9 inhibitors;
in such patients, other treatments (e.g., therapies
that target hepatic secretion of apolipoprotein B) are
needed.
FIGURE 2 Continued
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2647A second added beneﬁt of PCSK9 inhibitors is the
ability to lower the lipoprotein(a) concentration and,
hopefully, thereby also reduce the independent re-
sidual risk associated with elevated lipoprotein(a)
levels that has been demonstrated even among pa-
tients who have low LDL-C on statin therapy (58).
Statins and other commonly used oral lipid-lowering
therapies (other than nicotinic acid, which itself does
not reduce cardiovascular events when added to
a statin [59,60]) do not signiﬁcantly affect lip-
oprotein(a). Because lipoprotein(a) is not thought to
be cleared by the LDL-R but is mainly regulated by
hepatic secretion (61), further work is needed to
elucidate the mechanism through which PCSK9 in-
hibitors reduce lipoprotein(a). In addition, ongoing
studies may provide additional insight as to whether
the reduction in lipoprotein(a) obtained with PCSK9
inhibitors will translate into added clinical beneﬁt,
above and beyond that attributable to achieving a
lower LDL-C.
IMPLICATIONS FOR POPULATION HEALTH
Atherosclerotic cardiovascular disease remains the
leading cause of morbidity and mortality in devel-
oped countries, while rates are rapidly increasing in
developing regions. In the United States, the preva-
lence of CHD is 15.5 million (6.2%) in adults age
$20 years, with an estimated 635,000 new CHD
events occurring annually (62). In addition, thereare nearly 60 million Americans estimated to have
an LDL-C $160 mg/dl (63)—a level at which
high-intensity statin may be necessary to achieve
the desired 50% reduction in LDL-C. Yet even among
patients with established atherosclerosis, an analysis
in 2012 from a large U.S. managed-care database
demonstrated that only 26% of patients were
receiving a high-intensity statin (64). This likely
explains why only about one-third of very high-risk
patients achieve an LDL-C <70 mg/dl in surveys
conducted both within (65) and outside of the
United States (66). Whether the underutilization of
high-intensity statins is due to intolerance (which is
estimated to be only 10% to 20% of patients) and/or
patient or physician preference, the acceptance of
high-dose statin therapy has been slow over the
decade since the PROVE IT TIMI 22 (Pravastatin or
Atorvastatin Evaluation and Infection Therapy–
Thrombolysis In Myocardial Infarction 22) study ﬁrst
established its superiority over moderate-intensity
statin therapy in high-risk patients (67).
Whether the safety and tolerability proﬁle of the
PCSK9 MoAbs will continue to be as favorable as re-
ported in the phase 2 and early phase 3 studies re-
mains to be seen. However, their introduction into
clinical practice could result in a major shift in the
LDL-C population distribution (Figure 3) and has
the potential to have a large effect on future
atheroembolic events. As seen in the Mendelian
randomization studies of loss-of-function mutations
FIGURE 3 Shift in Distribution of LDL-C in a Population of High-Risk Individuals With
Use of PCSK9 Inhibitor
Population Effect
NCEP High-risk Pts in
LAPLACE-TIMI 57 Treated
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Effect of PCSK9 MoAb
In the LAPLACE-TIMI 57 (LDL-C Assessment with Proprotein Convertase Subtilisin Kexin
Type 9 Monoclonal Antibody Inhibition Combined with Statin Therapy-Thrombolysis In
Myocardial Infarction 57) trial, the mean LDL-C among stable, high-risk patients with
hypercholesterolemia was 123 mg/dl, a value that is similar to the average reported in
several surveys of the U.S. general population (23). With administration of 140 mg
every 2 weeks of evolocumab, the average LDL-C was reduced to a mean of 47 mg/dl, with
>90% of patients achieving an LDL-C <70 mg/dl. The majority of patients thus achieved
an LDL-C of 25 to 60 mg/dl, a range labeled as physiological for humans by Brown and
Goldstein in their 1985 Nobel Lecture. HDL-C ¼ high-density lipoprotein cholesterol;
revasc ¼ revascularization; other abbreviations as in Figures 1 and 2.
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2648in PCSK9, even a modest (15% to 28%) lifelong
reduction in LDL-C translates into a large (47% to
88%) reduction in CHD events (11). This raises the
possibility of a dramatic alteration in the population
burden of atherosclerosis if potent PCSK9 inhibition
could be safely and economically (e.g., at a price
similar to other currently available lipid therapies)
initiated earlier in life (i.e., primary prevention).
Although event rates in a primary prevention popu-
lation are considerably lower than in secondary pre-
vention, the CTT meta-analysis (50) of more intensive
LDL-C lowering observed a 25% reduction in major
vascular events for each 1 mmol/l (38.7 mg/dl)
reduction in LDL-C in patients without vascular dis-
ease. Moreover, among individuals at apparently low
risk clinically, genetics and other novel risk factors
could be used to identify subsets with higher risk
(68). If the relationship between LDL-C reduction and
clinical beneﬁt observed in the primary prevention
trials with statins holds true for PCSK9 inhibitors
(50), a 36% reduction in major vascular events would
be expected with PCSK monotherapy, compared
with placebo. This is comparable to the decline in
rates of CHD death or ﬁrst MI reported in a survey
of 4 U.S. communities over a 10-year period
(69), a trend that has been attributed to reducedrates of smoking, wider use of aspirin, and better
control of CHD risk factors, in particular more
frequent use of statins. However, the authors wish
to caution against excessive exuberance pending
the results of the ongoing cardiovascular outcome
trials. Furthermore, given increasing constraints on
health care spending and higher bars being set by
the Centers for Medicare and Medicaid Services for
coverage determination of novel therapies (70),
we anticipate the availability of MoAbs to PCSK9
will be limited initially to those patients who are
at high cardiovascular risk, with an LDL-C that is
not well controlled despite intensive therapy with
statin þ ezetimibe, or who cannot tolerate statin
therapy.
SUMMARY
In the 12 years since mutations in the PCSK9 gene
were identiﬁed as the third locus for FH, dozens of
clinical trials have demonstrated that potent reduc-
tion in LDL-C is possible with MoAbs directed against
the PCSK9 protein. In addition, these therapies
reduce a number of other atherogenic lipoproteins,
including apolipoprotein B, non-HDL total choles-
terol, and lipoprotein(a). The safety and tolerability
proﬁle of the 2 most extensively studied MoAbs
(alirocumab, evolocumab) for periods of up to 2 years
appears promising; however, longer exposure is
necessary to more completely evaluate potentially
delayed adverse effects, such as neurocognitive
impairment and cancer. Given the reduction in LDL-C
observed in phase 2 and 3 trials to date and the ana-
lyses of cardiovascular events in longer-term studies,
major vascular events could be reduced by 40% to
50% in high-risk patients if the beneﬁts follow a
similar relationship as that observed with statins.
This degree of clinical beneﬁt ought to be easily
within the reach of ongoing phase 3 cardiovascular
outcome studies with 3 PCSK9 MoAbs in a total of
>70,000 patients. Although the annals of clinical tri-
als are rife with “can’t miss” therapies that subse-
quently proved to be failures, the notion that both
statins and PCSK9 MoAbs result in an increase in
LDL-R activity on the hepatocyte surface (71) leads us
to conclude that PCSK9 inhibitors are well positioned
to become 1 of the next major breakthroughs in car-
diovascular therapeutics.
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